

ASX ANNOUNCEMENT

5 July 2022

VIRTUS HEALTH LIMITED (ASX: VRT)

Update on Takeover Offer

Virtus Health Limited (ACN 129 643 492) (**Virtus**) refers to the off-market takeover offer by Oceania Equity Investments Pty Ltd as trustee of the Oceania Trust and A.C.N. 658 293 166 Pty Ltd (**BGH Bidders**) for all of the issued shares of Virtus that the BGH Bidders do not already own (**Takeover Offer**).

Further to Virtus' ASX announcements of 29 June 2022, Virtus confirms that on 1 July 2022:

- a special dividend of \$0.30 per share was paid by EFT to eligible shareholders;¹
- in line with market practice, the consideration payable by the BGH Bidders under the Takeover Offer of \$7.855 per share was paid via cheques mailed to eligible shareholders that accepted the Takeover Offer, which eligible shareholders should receive from this week; and
- following the payments referenced above, the resignation of Ms Sonia Petering as director and Chair of Virtus took effect.

The BGH Bidders have also confirmed to Virtus that they intend to pursue compulsory acquisition of the shares held by shareholders who did not accept the Takeover Offer in accordance with the provisions of Chapter 6A of the *Corporations Act 2001* (Cth) and arrange for Virtus to be removed from the official list of ASX.

If you have any questions about the Takeover Offer, including payment of the consideration in connection with it, you can call the BGH Offer Information Line on 1300 620 418 (tollfree within Australia) or +61 3 9415 4656 (from outside Australia).

This announcement is authorised by the Virtus Board.

-ENDS-

¹ In order to be eligible to receive the special dividend, you must have been a Virtus shareholder on the record date for the special dividend of 20 June 2022.



Further information:

Investor Enquiries:

Matt Prior
CFO, Virtus Health
+61 2 9425 1722
matthew.prior@virtushealth.com.au

Virtus Health Limited (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful ARS collaborations in the world. With 126 of the world's leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia, Ireland and Denmark, Singapore and UK.